Results 161 to 170 of about 18,044 (266)

Increased Serum Neurofilament Light Chain Levels in Parkinson's Disease Patients Carrying the p.A53T SNCA Mutation: Data from the Parkinson's Progression Markers Initiative Study

open access: yesMovement Disorders, EarlyView.
Abstract Background Serum neurofilament light chain (NfL) levels, a marker of axonal damage, are generally elevated in neurodegenerative conditions, but results in idiopathic Parkinson's disease (iPD) have been inconsistent. The p.A53T SNCA mutation usually leads to a severe form of PD.
Nikolaos Papagiannakis   +213 more
wiley   +1 more source

Effectiveness and Safety of RHA3 vs a Comparator Product for Lip Augmentation: A Randomized, Controlled, Prospective, Multicenter Clinical Study. [PDF]

open access: yesAesthet Surg J
Weinkle S   +8 more
europepmc   +1 more source

Diagnostic Value of Glycocalyx Shedding in Blood for Differentiating between Parkinson's Disease and Multiple System Atrophy

open access: yesMovement Disorders, EarlyView.
Abstract Background Blood–brain barrier disruption is increasingly recognized in synucleinopathies, but the role of the endothelial glycocalyx (GLX) in Parkinson's disease (PD) and multiple system atrophy (MSA) remains unclear. Objectives The aim was to determine whether plasma GLX markers differ between PD, MSA, and healthy controls (HC), relate to ...
Jonas Folke   +15 more
wiley   +1 more source

Adaptive Deep Brain Stimulation for Parkinson's Disease: Navigating the Roadblocks to Clinical Implementation

open access: yesMovement Disorders, EarlyView.
Abstract Adaptive deep brain stimulation (aDBS) represents an important evolution in the treatment of Parkinson's disease (PD), building on conventional DBS (cDBS) by adjusting stimulation in response to real‐time physiological signals. By enabling dynamic targeting of disease‐related neural activity, aDBS offers the potential for more precise ...
Thomas Koeglsperger   +5 more
wiley   +1 more source

Systematic Review of the Huntington's Disease Drug Development Pipeline, 2014 to 2025

open access: yesMovement Disorders, EarlyView.
Abstract Background In the past decade, significant advances have improved our understanding of the mechanisms underlying HD pathobiology leading to several putative therapeutic targets for HD. Objective The aim was to describe the Huntington's disease (HD) drug development clinical pipeline.
Pavlina Konstantinova   +5 more
wiley   +1 more source

How Can We Improve the Assessment and Indifferent Outcomes From Pelvic Organ Prolapse Management From Conservative and Surgical Therapies? ICI‐RS 2025

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Pelvic organ prolapse is a common condition and many women seek surgical treatment for prolapse symptoms. However, recurrence of prolapse after surgical treatment is common. A think tank was held at ICI‐RS 2025 to discuss how the assessment and indifferent results from conservative and surgical management can be improved.
Rohna Kearney   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy